Global Bronchopulmonary Dysplasia Drug Market 2020

                                          
About Bronchopulmonary Dysplasia(Facts, Figures & Treatment):
 As per an article from WHO, more than 15 million babies are born prematurely worldwide. Also, an estimated 10,000 to 15,000 newborns develop BPD in the United States every year. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that affects newborns. Most infants who develop BPD have been born prematurely and need oxygen therapy. Most infants recover from BPD, but some may have long-term breathing difficulties. In BPD the lungs and the airways (bronchi) are damaged, causing tissue destruction (dysplasia) in the tiny air sacs of the lung (alveoli).

In the lungs, BPD causes damage to the current and developing alveoli. Additionally, the tiny blood vessels surrounding the alveoli may be affected, making the passage of blood through the lungs more difficult. The lower the number of working alveoli, the longer the infant may need to remain on a ventilator, which can cause further damage to the child’s lungs. As the lungs of a newborn  are particularly vulnerable, high amounts of inhaled oxygen and pressure may overstretch the alveoli, causing inflammation and damage to the inside lining of the airways, the alveoli and the blood vessels around them. These effects are particularly damaging on the premature lung. BPD is considered to be primarily a complication of prematurity. Although, different conditions may affect the growth of the fetus during the pregnancy and may also lead to premature labor. Prenatal infections or maternal complications such as smoking, drug use, placental abnormalities (preeclampsia) and inflammation of the fetal membranes (chorioamnionitis) may cause BPD.

The degree of prematurity in an infant is largely what puts a child at risk of developing BPD. A majority of newborns who develop BPD are born more than 10 weeks early, weigh less than two pounds at birth, and are born with breathing problems. BPD is rare in infants born after 32 weeks of pregnancy.

In the long run, increased pressure inside the blood vessels in the lungs and between the heart and lungs can cause pulmonary hypertension. In severe cases, heart failure can occur. Newborns who suffer from BPD may also experience trouble feeding, leading to delayed development.

Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants. The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.

The global Bronchopulmonary Dysplasia Drug market is valued at million US$ in 2020 is expected to reach million US$ by the end of 2029, growing at a CAGR of during 2021-2029.

This report focuses on Bronchopulmonary Dysplasia Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bronchopulmonary Dysplasia Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

 	
Chiesi Farmaceutici SpA
 	
Insmed Inc
 	
Martindale Pharmaceuticals Ltd
 	
MediPost Co Ltd
 	
Meridigen Biotech Co Ltd
 	
Therabron Therapeutics Inc
 	
Retail Business Services , LLC.
 	
Geiss, Destin & Dunn Inc.
 	
Cardinal Health
 	
Healthlife of Usa
 	
Hikma Pharmaceuticals USA Inc.
 	
AMERICAN REGENT, INC.
 	
Paddock Laboratories, Inc.
 	
Armas Pharmaceuticals Inc.
 	
Sun Pharmaceutical Industries, Inc.
 	
Sagent Pharmaceuticals
 	
Exela Pharma Sciences, LLC
 	
AstraZeneca Pharmaceuticals LP
 	
Prometheus Laboratories
 	
Rising Pharmaceuticals, Inc.

Segment by Type

 	
Budesonide
 	
Caffeine Citrate (Caffeine Citrate Injection (the generic equivalent of Hikma's, CAFCIT®), has an approximate market size of $4M, annually in the USA)
 	
CG-100
 	
Others

Segment by Application

 	
Hospital
 	
Clinic
 	
Others

Key Developments and Approval for Bronchopulmonary Dysplasia Drug in 2020

In August 2020,Gennisium Pharma received marketing authorization valid throughout the European Union for Gencebok which is a stimulant medicine used for treating apnoea of prematurity, a condition in which babies born prematurely stop breathing for longer than 20 seconds. Gencebok contains the active substance caffeine citrate. Gencebok is a hybrid medicine, containing the same active substance, but at a different strength. The reference medicine for Gencebok is Peyona. Apnoea in premature babies occurs because the part of the babys brain that controls breathing (breathing centre) is not fully developed. Caffeine citrate, the active substance in Gencebok, blocks the effect of adenosine. Adenosine is a natural substance that slows down the activity of some parts of the brain including the breathing centre. By reducing the effect of adenosine, caffeine citrate stimulates the brain to restore breathing. Gennisium also granted exclusive licence to Reach-Pharma for Gencebok® in Australia, New-Zealand and Papua-New Guinea. Additionally, Gennisium expanded its presence in the most important markets in Latin America, Mexico and Brazil, in granting exclusive promotion rights to Moksha8 for Gencebok®

Caffeine Citrate Injection (the generic equivalent of Hikma's, CAFCIT®), available in 60mg/3mL; has an approximate market size of $4M, annually.